Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis

Oncogene

Volumn 32, Issue 27, 2013, Pages 3286-3295

  Dong, P ^a   Karaayvaz, M ^b   Jia, N ^c   Kaneuchi, M ^a   Hamada, J ^d   Watari, H ^a   Sudo, S ^a   Ju, J ^b   Sakuragi, N ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Cancer; EMT; Gain of function; miRNA; p53 mutation

Indexed keywords

KRUPPEL LIKE FACTOR 4; MICRORNA; MICRORNA 130B; NERVE CELL ADHESION MOLECULE; PROTEIN P53; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ARTICLE; CANCER CELL; CANCER PROGNOSIS; EPITHELIAL MESENCHYMAL TRANSITION; GAIN OF FUNCTION MUTATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR INVASION;

AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MICRORNAS; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84880298880     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.334     Document Type: Article

References (49)

1. Kang Y, Massagué J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004; 118: 277-279.
2. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelialmesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910-14914.
3. Li Y, VandenBoom 2nd TG, Kong D, Wang Z, Ali S, Philip PA et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-tomesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009; 69: 6704-6712.
4. Meng Z, Fu X, Chen X, Zeng S, Tian Y, Jove R et al. miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology 2010; 52: 2148-2157.
5. Kim T, Veronese A, Pichiorri F, Lee TJ, Jeon YJ, Volinia S et al. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 2011; 208: 875-883.
6. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW et al. p53 regulates epithelialmesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 2011; 13: 317-323.
7. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer 2011; 2: 466-474.
8. Scian MJ, Stagliano KE, Anderson MA, Hassan S, Bowman M, Miles MF et al. Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol 2005; 25: 10097-10110.
9. Xi Y, Formentini A, Chien M, Weir DB, Russo JJ, Ju J et al. Prognostic values of microRNAs in colorectal cancer. Biomark Insights 2006; 2: 113-121.
10. Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, Madar S et al. Mutant p53 (R175H) upregulates Twist1 expression and promotes epithelialmesenchymal transition in immortalized prostate cells. Cell Death Differ 2011; 18: 271-281.
11. Fujisawa T, Watanabe J, Kamata Y, Hamano M, Hata H, Kuramoto H. VEGF expression and its reguration by p53 gene transfection in endometrial carcinoma cells. Hum Cell 2003; 16: 47-54.
12. Singh A, Settleman J. EMT cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741-4751.
13. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A et al. The EMTactivator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11: 1487-1495.
14. Singh M, Spoelstra NS, Jean A, Howe E, Torkko KC, Clark HR et al. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Mod Pathol 2008; 21: 912-923.
15. Clapé C, Fritz V, Henriquet C, Apparailly F, Fernandez PL, Iborra F et al. miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS One 2009; 4: e7542.
16. Dong P, Kaneuchi M, Watari H, Hamada J, Sudo S, Ju J et al. MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer 2011; 10: 99.
17. Forrest AR, Kanamori-Katayama M, Tomaru Y, Lassmann T, Ninomiya N, Takahashi Y et al. Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation. Leukemia 2010; 24: 460-466.
18. Bandres E, Bitarte N, Arias F, Agorreta J, Fortes P, Agirre X et al. MicroRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res 2009; 15: 2281-2290.
19. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 2009; 69: 1279-1283.
20. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007; 26: 731-743.
21. Song B, Wang Y, Kudo K, Gavin EJ, Xi Y, Ju J. miR-192 Regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit. Clin Cancer Res 2008; 14: 8080-8086.
22. Castilla MÁ, Moreno-Bueno G, Romero-Pé rez L, Van De Vijver K, Biscuola M, Ló pez- García MÁ et al. Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol 2011; 223: 72-80.
23. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 2009; 8: 1055-1066.
24. Xi Y, Shalgi R, Fodstad O, Pilpel Y, Ju J. Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. Clin Cancer Res 2006; 12: 2014-2024.
25. Scian MJ, Stagliano KE, Deb D, Ellis MA, Carchman EH, Das A et al. Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes. Oncogene 2004; 23: 4430-4443.
26. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010; 2: a001107.
27. Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 2010; 467: 986-990.
28. Navon R, Wang H, Steinfeld I, Tsalenko A, Ben-Dor A, Yakhini Z. Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS One 2009; 4: e8003.
29. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
30. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA 2008; 105: 7004-7009.
31. Frazier MW, He X, Wang J, Gu Z, Cleveland JL, Zambetti GP. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol 1998; 18: 3735-3743.
32. Sun Y, Cheung JM, Martel-Pelletier J, Pelletier JP, Wenger L, Altman RD et al. Wild type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13). J Biol Chem 2000; 275: 11327-11332.
33. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992; 255: 459-462.
34. Kim E, Deppert W. Transcriptional activities of mutant p53: when mutations are more than a loss. J Cell Biochem 2004; 93: 878-886.
35. Zalcenstein A, Stambolsky P, Weisz L, Müller M, Wallach D, Goncharov TM et al. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene 2003; 22: 5667-5676.
36. Weisz L, Zalcenstein A, Stambolsky P, Cohen Y, Goldfinger N, Oren M et al. Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res 2004; 64: 8318-8327.
37. Zalcenstein A, Weisz L, Stambolsky P, Bar J, Rotter V, Oren M. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. Oncogene 2006; 25: 359-369.
38. Gualberto A, Baldwin Jr AS. p53 and Sp1 interact and cooperate in the tumor necrosis factor-induced transcriptional activation of the HIV-1 long terminal repeat. J Biol Chem 1995; 270: 19680-19683.
39. Chicas A, Molina P, Bargonetti J. Mutant p53 forms a complex with Sp1 on HIV-LTR DNA. Biochem Biophys Res Commun 2000; 279: 383-390.
40. Imbriano C, Gurtner A, Cocchiarella F, Di Agostino S, Basile V, Gostissa M et al. Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters. Mol Cell Biol 2005; 25: 3737-5371.
41. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006; 10: 191-202.
42. McLure KG, Lee PW. p53 DNA binding can be modulated by factors that alter the conformational equilibrium. EMBO J 1999; 18: 763-770.
43. Zhang W, Funk WD, Wright WE, Shay JW, Deisseroth AB. Novel DNA binding of p53 mutants and their role in transcriptional activation. Oncogene 1993; 8: 2555-2559.
44. Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006; 99: 671-678.
45. Yip L, Kelly L, Shuai Y, Armstrong MJ, Nikiforov YE, Carty SE et al. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol 2011; 18: 2035-2041.
46. Yang C, Cai J, Wang Q, Tang H, Cao J, Wu L et al. Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1. Gynecol Oncol 2012; 124: 325-334.
47. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, Castilho A et al. miR-130b promotes CD133 (+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010; 7: 694-707.
48. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T et al. p53-responsive microRNAs 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 2008; 68: 10094-10104.
49. Dong P, Xu Z, Jia N, Li D, Feng Y. Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway. Mol Cancer 2009; 8: 103-110.